<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, diagnosis, and treatment of osteomalacia in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, diagnosis, and treatment of osteomalacia in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, diagnosis, and treatment of osteomalacia in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adi Cohen, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew T Drake, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah E Sellmeyer, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 16, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Osteomalacia is a bone disorder characterized by decreased mineralization of newly formed osteoid at sites of bone turnover. Osteomalacia can result from different etiologies via mechanisms that result in hypocalcemia, hypophosphatemia, or direct inhibition of the mineralization process. In adults, nutritional osteomalacia due to vitamin D deficiency is the most common etiology.</p><p>This topic review will present an overview of the clinical manifestations, diagnosis, and treatment of adults with osteomalacia. The clinical manifestations, diagnosis, and treatment of nutritional rickets in children, as well as rickets due to hereditary vitamin D resistance, 1-alpha-hydroxylase deficiency, and hereditary hypophosphatemic disorders that present before adulthood are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5804.html" rel="external">"Etiology and treatment of calcipenic rickets in children"</a> and  <a class="medical medical_review" href="/z/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia"</a>.)</p><p>The epidemiology and causes of osteomalacia also are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia"</a>.)</p><p class="headingAnchor" id="H3169580"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H29575908"><span class="h2">Clinical findings</span><span class="headingEndMark"> — </span>In early stages, osteomalacia is often asymptomatic. With progression, it can produce characteristic symptoms that are not specific to the underlying cause. These include diffuse bone and joint pain, muscle weakness, and difficulty walking [<a href="#rid1">1-3</a>]. Symptoms may be insidious in onset. Many symptoms of osteomalacia can mimic other skeletal, rheumatologic, and systemic illnesses; diagnosis is often delayed and requires a high degree of clinical suspicion.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone pain</strong> – Bone pain is usually most pronounced in the lower spine, pelvis, and lower extremities, as well as where fractures have occurred, and may be associated with tenderness to palpation. The pain is characterized as dull and aching and is aggravated by activity and weight bearing. Bone pain is not a feature of osteoporosis; bone pain in a patient with a history of fragility fracture(s) should raise concern that the underlying process is osteomalacia rather than osteoporosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Muscle weakness</strong> – Muscle weakness is usually proximal and may be associated with muscle wasting, hypotonia, and discomfort with movement [<a href="#rid1">1</a>]. Muscle weakness may lead to a waddling gait and is a frequent finding in osteomalacia due to vitamin D deficiency or disorders of phosphorus metabolism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fractures</strong> – Fractures may occur with little or no trauma and typically involve the ribs, vertebrae, pelvis, and long bones. Hypophosphatasia can present with a different fracture pattern that is generally nonvertebral and often includes slow healing metatarsal or other lower extremity fractures [<a href="#rid4">4</a>]. Atypical femur fractures may occur in adults with hypophosphatasia, both in untreated patients and in those inappropriately treated with antiresorptive therapy for osteoporosis [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone deformity</strong> – Abnormal spinal curvature or deformity of the thorax or pelvis appears only in severe osteomalacia of long duration [<a href="#rid1">1</a>].</p><p></p><p>Additional findings may be present depending on the underlying etiology. For example, etiologies that lead to hypocalcemia may present with muscle cramps, paresthesias, and physical examination findings of neuromuscular irritability (eg, Trousseau's sign, Chvostek's sign). Osteomalacia secondary to hypophosphatasia, caused by mutations in the <em>ALPL</em> gene, may be associated with chondrocalcinosis and premature loss of teeth during childhood and adulthood [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia", section on 'Hypophosphatasia'</a>.)</p><p>In a report of 17 patients with osteomalacia on bone biopsy, the following findings were observed [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Bone pain and muscle weakness in 16 (94 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Bone tenderness in 15 (88 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Fracture in 13 (76 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Difficulty walking and waddling gait in four (24 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Muscle spasms, cramps, a positive Chvostek's sign, tingling/numbness, and inability to ambulate in one to two (6 to 12 percent)</p><p></p><p class="headingAnchor" id="H15280944"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Laboratory abnormalities in patients with osteomalacia largely depend on the underlying cause  (<a class="graphic graphic_table graphicRef65400" href="/z/d/graphic/65400.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef142633" href="/z/d/graphic/142633.html" rel="external">algorithm 1</a>). The interpretation of laboratory tests in the evaluation of osteomalacia is discussed below. (See <a class="local">'Laboratory tests'</a> below.)</p><p>In retrospective reviews of patients with biopsy-proven nutritional osteomalacia, the following laboratory abnormalities were observed [<a href="#rid7">7,8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Alkaline phosphatase elevated in 95 to 100 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Serum calcium and phosphorus reduced in 27 to 38 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary calcium low in 87 percent</p><p class="bulletIndent1"><span class="glyph">●</span>25-hydroxyvitamin D (25[OH]D, calcidiol) &lt;15 ng/mL (37 nmol/L) in 100 percent</p><p class="bulletIndent1"><span class="glyph">●</span>PTH elevated in 100 percent</p><p></p><p>Most patients (40 of 43) in these reviews had nutritional osteomalacia from either gastrointestinal malabsorption or suboptimal nutrition and inadequate sun exposure. In these cases, 25(OH)D levels were very low (almost uniformly &lt;12 ng/mL [30 nmol/L] and all &lt;15 ng/mL [37.5 nmol/L]), which is generally not the case in other causes of osteomalacia, such as the renal phosphate wasting syndromes. (See <a class="local">'Severe vitamin D deficiency'</a> below and <a class="local">'Alternative etiology suspected'</a> below.)</p><p class="headingAnchor" id="H3169587"><span class="h2">Imaging findings</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiographic findings</strong> – In adults with osteomalacia, radiographic evidence of reduced bone mineral density (BMD) with thinning of the cortex is the most common finding but is very nonspecific. More specific are changes in vertebral bodies and Looser zones. Infrequently, radiographic evidence of secondary hyperparathyroidism can be seen. These more specific findings are part of the diagnostic evaluation and discussed in detail below. (See <a class="local">'Skeletal imaging for suspected osteomalacia'</a> below.)</p><p></p><p class="bulletIndent1">The radiographic abnormalities in adults with osteomalacia are less striking than those seen in children with rickets [<a href="#rid9">9-13</a>]. (See  <a class="medical medical_review" href="/z/d/html/5856.html" rel="external">"Overview of rickets in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BMD</strong> – Depending on the underlying etiology of osteomalacia, BMD measured by dual-energy x-ray absorptiometry (DXA) may be decreased, normal, or increased. In patients with osteomalacia due to vitamin D deficiency, several studies have demonstrated markedly reduced spine, hip, and forearm BMD (as measured by DXA) [<a href="#rid7">7,8</a>]. In contrast, BMD may be normal or increased (especially at the lumbar spine) in adults with X-linked hypophosphatemia, axial osteomalacia, hypophosphatasia, fibrogenesis imperfecta, and skeletal fluorosis [<a href="#rid14">14-16</a>]. (See  <a class="medical medical_review" href="/z/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia", section on 'X-linked hypophosphatemia'</a> and  <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia", section on 'Defective bone matrix'</a>.)</p><p></p><p class="headingAnchor" id="H29575819"><span class="h1">DIAGNOSTIC AND ETIOLOGIC EVALUATION</span></p><p class="headingAnchor" id="H2454968800"><span class="h2">Whom to evaluate</span><span class="headingEndMark"> — </span>Osteomalacia may be difficult to diagnosis. It should be suspected in any adult with bone pain and tenderness. It also should be suspected in younger or middle-aged adults with low bone mineral density (BMD) or atraumatic fracture in the absence of a known secondary cause of bone loss (eg, glucocorticoid use). The diagnosis is supported by the presence of risk factors such as conditions associated with gastrointestinal malabsorption, chronic liver disease, or chronic kidney disease. (See <a class="local">'Clinical history and physical examination'</a> below.)</p><p>A high index of clinical suspicion for osteomalacia is important because symptoms are generally nonspecific, and a delay in diagnosis is common [<a href="#rid7">7,17,18</a>]. In one study of 33 women with osteomalacia, the mean duration of symptoms before diagnosis was 2.5 years [<a href="#rid17">17</a>]. Diagnoses considered prior to confirmation of osteomalacia included osteoporosis, Paget disease of bone, malignancy, pseudohypoparathyroidism, osteoarthritis, malabsorption, irritable bowel syndrome with depression, fibromyalgia, and somatization disorders. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Osteoporosis and osteomalacia may coexist. In a cross-sectional study of 72 older adults (mean age 70.4 years) presenting with low trauma hip fracture, approximately 30 percent of participants met histologic criteria for osteomalacia [<a href="#rid19">19</a>]. Mixed skeletal pathology with a component of osteomalacia also may be evident in individuals with chronic kidney disease. (See  <a class="medical medical_review" href="/z/d/html/7239.html" rel="external">"Evaluation of renal osteodystrophy", section on 'Subtypes of renal osteodystrophy'</a>.)</p><p class="headingAnchor" id="H4081076718"><span class="h2">Approach to evaluation</span><span class="headingEndMark"> — </span>The diagnosis of osteomalacia is based on clinical, radiographic, and laboratory findings. Laboratory findings are variable and specific to the underlying cause  (<a class="graphic graphic_table graphicRef65400" href="/z/d/graphic/65400.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef142633" href="/z/d/graphic/142633.html" rel="external">algorithm 1</a>); thus, laboratory data help both verify the diagnosis and identify the underlying cause. (See <a class="local">'Laboratory tests'</a> below.)</p><p>Transiliac crest bone biopsy with double <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> labeling and histomorphometric assessment is the most accurate way to diagnose osteomalacia and is considered the gold standard. However, it is infrequently performed clinically because it is invasive, not widely available, and is rarely required to establish the diagnosis in patients with normal kidney function. Indications for bone biopsy are reviewed below. (See <a class="local">'Bone biopsy if the diagnosis or etiology remains uncertain (rarely performed)'</a> below.)</p><p>The diagnosis of genetic causes of osteomalacia and rickets that typically present before adulthood (eg, 1-alpha-hydroxylase deficiency, vitamin D resistance, X-linked hypophosphatemia) is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5804.html" rel="external">"Etiology and treatment of calcipenic rickets in children", section on 'Defects in vitamin D metabolism'</a> and  <a class="medical medical_review" href="/z/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia"</a>.)</p><p class="headingAnchor" id="H559450323"><span class="h2">Clinical history and physical examination</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical history </strong>– In adults with suspected osteomalacia, clinical history should elicit both bone-related symptoms and potential risk factors for specific etiologies. We assess for the following risk factors for osteomalacia:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nutritional risk factors</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>History of bariatric surgery, cystic fibrosis, or gastrointestinal disease (eg, celiac disease, inflammatory bowel disease) suggest possible nutritional osteomalacia due to gastrointestinal malabsorption.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>General undernutrition and low intake of common food sources of calcium and vitamin D  (<a class="graphic graphic_table graphicRef77982" href="/z/d/graphic/77982.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef67824" href="/z/d/graphic/67824.html" rel="external">table 3</a>) are risk factors for nutritional osteomalacia. Individuals with limited sun exposure (eg, homebound or hospitalized adults) are similarly at risk for vitamin D deficiency. (See  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Groups at high risk'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Kidney or liver dysfunction</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Chronic kidney disease leads to reduced 1,25-dihydroxyvitamin D (<a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a>) through diminished renal 1-alpha-hydroxylase activity. Treatment with aluminum or iron also may contribute to osteomalacia in the setting of chronic kidney disease. (See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Abnormalities of parathyroid hormone, calcium, phosphorus, fibroblast growth factor 23, and vitamin D metabolism'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Multiple myeloma or amyloidosis suggests osteomalacia may be due to generalized proximal tubule dysfunction (acquired Fanconi syndrome).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Chronic liver disease can lead to osteomalacia through multiple mechanisms, including loss of 25-hydroxylation of vitamin D or decreased bile acid secretion with consequent malabsorption. (See  <a class="medical medical_review" href="/z/d/html/3606.html" rel="external">"Evaluation and treatment of low bone mass in primary biliary cholangitis (primary biliary cirrhosis)", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medications</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Certain medications (eg, carbonic anhydrase inhibitors, certain antiretroviral therapies, enzyme-inducing antiseizure medications) may cause osteomalacia due to proximal (type 2) renal tubular acidosis. (See  <a class="medical medical_review" href="/z/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Proximal (type 2) RTA'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Some antiseizure medications can cause vitamin D deficiency due to accelerated vitamin D catabolism. (See  <a class="medical medical_review" href="/z/d/html/2063.html" rel="external">"Antiseizure medications and bone disease", section on 'Effect of ASM type'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Some intravenous iron formulations (eg, <a class="drug drug_general" data-topicid="90237" href="/z/d/drug information/90237.html" rel="external">ferric carboxymaltose</a>) have been associated with osteomalacia due to fibroblast growth factor 23 (FGF23)-mediated hypophosphatemia [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The bisphosphonate <a class="drug drug_general" data-topicid="8426" href="/z/d/drug information/8426.html" rel="external">etidronate</a> can cause osteomalacia through direct inhibition of mineralization. Other bisphosphonates do not cause osteomalacia. (See  <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia", section on 'Mineralization inhibitors'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Excessive ingestion of aluminum salts in antacids can lead to osteomalacia due to inhibition of gastrointestinal phosphate absorption and consequent hypophosphatemia [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Metal and mineral exposures</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Exposures to fluoride or aluminum suggest osteomalacia due to a mineralization inhibitor. Excessive fluoride exposure may result, for example, from ingestion of fluoride-containing dental products or inhalation of electronic or computer cleaning products ("huffing"). (See  <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia", section on 'Mineralization inhibitors'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Exposure to heavy metals (eg, lead, copper, cadmium) may cause osteomalacia due to proximal (type 2) renal tubular acidosis or through direct effects on mineralization. (See  <a class="medical medical_review" href="/z/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Proximal (type 2) RTA'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – In adults with osteomalacia, skeletal deformities are rare. Findings such as mild short stature, long bone bowing, and/or tooth loss suggest a possible inherited bone disorder such as X-linked hypophosphatemia or hypophosphatasia; these disorders can have subtle presentations and remain undetected until adulthood. On examination, focal or diffuse tenderness of bones strongly suggests osteomalacia. Kyphosis and height loss may develop consequent to multiple vertebral compression fractures. Abnormal gait due to proximal muscle weakness may be present in severe disease. With etiologies of osteomalacia that cause hypocalcemia, signs of tetany (eg, Trousseau's sign, Chvostek's sign) may be present. In tumor-induced osteomalacia, subcutaneous tumors may be palpable, particularly in the extremities [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H1835333436"><span class="h2">Skeletal imaging for suspected osteomalacia</span></p><p class="headingAnchor" id="H2120938574"><span class="h3">Imaging tests</span><span class="headingEndMark"> — </span>In adults with suspected osteomalacia, we obtain plain radiographs of the spine and other skeletal regions based on localized signs and symptoms (eg, areas of pain, tenderness, or deformity). Although no imaging findings are exclusive to osteomalacia, certain findings can support the diagnosis.</p><p>BMD measurement is not required for the diagnosis of osteomalacia, and reduced BMD does not distinguish osteoporosis from osteomalacia. However, once a diagnosis of osteomalacia is established, BMD measurement is performed to determine the severity of bone loss and provide a baseline for subsequent monitoring. (See <a class="local">'Monitoring'</a> below.)</p><p class="headingAnchor" id="H3025965933"><span class="h3">Diagnostic findings</span><span class="headingEndMark"> — </span>Radiographic findings of hallmark vertebral body changes or Looser zones help confirm the diagnosis. Additional findings may be present in severe disease or osteomalacia due to longstanding secondary hyperparathyroidism. However, the absence of these radiographic findings does not exclude osteomalacia; abnormal laboratory findings evolve earlier in disease course, and laboratory testing is therefore more sensitive than skeletal imaging. (See <a class="local">'Laboratory tests'</a> below.)</p><p class="headingAnchor" id="H3374327225"><span class="h4">Vertebral body changes</span><span class="headingEndMark"> — </span>Inadequate mineralization of osteoid and loss of secondary trabeculae lead to a loss of radiologic distinctness of vertebral body trabeculae, making the radiograph appear of poor quality  (<a class="graphic graphic_diagnosticimage graphicRef56149" href="/z/d/graphic/56149.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef87021" href="/z/d/graphic/87021.html" rel="external">image 2</a>). With more advanced disease, softening leads to a concavity of the vertebral bodies, sometimes called "codfish vertebrae." The vertebral disks appear large and biconvex. Spinal compression fractures may occur, but these are more common in osteoporosis.</p><p class="headingAnchor" id="H3240194198"><span class="h4">Looser zones</span><span class="headingEndMark"> — </span>Looser zones, commonly referred to as pseudofractures, are insufficiency fractures and are typically associated with pain. On radiograph, they appear as narrow, radiolucent lines, 2 to 5 mm in width with sclerotic borders. They lie perpendicular to the cortical margins of bones and are a characteristic radiologic finding in osteomalacia, typically late in the disease course  (<a class="graphic graphic_diagnosticimage graphicRef52768" href="/z/d/graphic/52768.html" rel="external">image 3</a>) [<a href="#rid9">9</a>]. Looser zones are not exclusively found in osteomalacia. However, in individuals with clinical symptoms consistent with osteomalacia, Looser zones are usually sufficient to confirm the diagnosis if they are bilateral, symmetric, and/or found at sites characteristic for osteomalacia. The most common sites include the femoral neck, the medial part of the femoral shaft, immediately under or a few centimeters beneath the lesser trochanter, and the pubic and ischial rami. They may also occur at the ulna, scapula, clavicle, rib, and metatarsal bones.</p><p>The term "Milkman syndrome" refers to the combination of multiple bilateral and symmetric pseudofractures in a patient with osteomalacia [<a href="#rid11">11</a>]. Pseudofractures can also be seen with bone scans (skeletal scintography) where they appear as hot spots (ie, focal areas of increased radiotracer activity) [<a href="#rid10">10</a>]. Increased radiotracer uptake in the costochondral junctions of the ribs may be evident ("rachitic rosary sign"); however, skeletal scintigraphy is not usually needed in the diagnostic evaluation of osteomalacia.</p><p>Looser zones (pseudofractures) reflect impaired repair of bone after injury due to mechanical stress. Whereas some locations are typical for stress fracture, in other locations, Looser zones may result from erosion of bone by arterial pulsations [<a href="#rid12">12,13</a>]. This latter mechanism is consistent with the bilateral, symmetric pattern of Looser zones and their frequent location in apposition to arteries [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H1060435491"><span class="h4">Other radiographic findings</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe osteomalacia</strong> – More severe osteomalacia can lead to shortening and bowing of the tibia, pathologic fractures, coxa profunda hip deformity  (<a class="graphic graphic_diagnosticimage graphicRef79529 graphicRef57357" href="/z/d/graphic/79529.html" rel="external">image 4A-B</a>), and cephalopelvic disproportion  (<a class="graphic graphic_diagnosticimage graphicRef87020" href="/z/d/graphic/87020.html" rel="external">image 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary hyperparathyroidism</strong> – Skeletal changes induced by longstanding secondary hyperparathyroidism (eg, from severe vitamin D deficiency) are less common. These include subperiosteal resorption of the phalanges, bone cysts, and resorption of the distal ends of long bones such as the clavicle and humerus. (See  <a class="medical medical_review" href="/z/d/html/2031.html" rel="external">"Primary hyperparathyroidism: Clinical manifestations", section on 'Skeletal'</a>.)</p><p></p><p class="headingAnchor" id="H3967594816"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>Laboratory findings are used to both confirm the diagnosis of osteomalacia and determine the underlying etiology  (<a class="graphic graphic_table graphicRef65400" href="/z/d/graphic/65400.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef142633" href="/z/d/graphic/142633.html" rel="external">algorithm 1</a>). Laboratory tests are usually performed simultaneously with imaging studies once the diagnosis of osteomalacia is suspected. The initial laboratory evaluation should include measurement of serum concentrations of:</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium</p><p class="bulletIndent1"><span class="glyph">●</span>Phosphate</p><p class="bulletIndent1"><span class="glyph">●</span>Alkaline phosphatase (total and bone specific [if available and clinical suspicion for osteomalacia is high])</p><p class="bulletIndent1"><span class="glyph">●</span>25-hydroxyvitramin D (25[OH]D)</p><p class="bulletIndent1"><span class="glyph">●</span>Parathyroid hormone (PTH)</p><p class="bulletIndent1"><span class="glyph">●</span>Electrolytes, blood urea nitrogen (BUN), and creatinine</p><p></p><p>The goal of the laboratory evaluation is to distinguish nutritional osteomalacia due to vitamin D and/or calcium deficiency from phosphate wasting syndromes and other less common causes of osteomalacia  (<a class="graphic graphic_table graphicRef65400" href="/z/d/graphic/65400.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef142633" href="/z/d/graphic/142633.html" rel="external">algorithm 1</a>). The serum 25(OH)D level distinguishes vitamin D deficiency, the most common etiology of osteomalacia, from other potential etiologies.</p><p class="headingAnchor" id="H3822048533"><span class="h3">Severe vitamin D deficiency</span><span class="headingEndMark"> — </span>In osteomalacia due to vitamin D deficiency, 25(OH)D (calcidiol) is typically very low (eg, &lt;12 to 15 ng/mL [30 to 37.5 nmol/L]). Lesser degrees of vitamin D deficiency are common but only rarely associated with osteomalacia [<a href="#rid24">24</a>], warranting consideration of other etiologies. (See <a class="local">'Alternative etiology suspected'</a> below.)</p><p>In addition to secondary hyperparathyroidism, biochemical findings of osteomalacia due to vitamin D deficiency include low to low-normal calcium and phosphate levels and an elevated alkaline phosphatase (both total and bone specific) [<a href="#rid1">1</a>]. Due to 1-alpha-hydroxylase stimulation by PTH, the serum concentration of 1,25-dihydroxyvitamin D may be normal, low, or high, depending upon the severity and duration of vitamin D deficiency, and is therefore not helpful in making the diagnosis [<a href="#rid25">25</a>].</p><p>Vitamin D deficiency may be due to various etiologies. The cause can usually be determined based on clinical history. Nutritional osteomalacia is most common and results from limited sun exposure with inadequate vitamin D intake or gastrointestinal malabsorption. (See  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Groups at high risk'</a>.)</p><p>Vitamin D deficiency also may result from advanced liver disease, nephrotic syndrome, or medications that accelerate vitamin D catabolism (eg, selected antiseizure medications). (See  <a class="medical medical_review" href="/z/d/html/2048.html" rel="external">"Causes of vitamin D deficiency and resistance", section on 'Calcidiol (25-hydroxyvitamin D)'</a>.)</p><p class="headingAnchor" id="H3203663387"><span class="h3">Alternative etiology suspected</span><span class="headingEndMark"> — </span>If severe vitamin D deficiency is excluded (eg, 25[OH]D level ≥12 to 15 ng/mL [30 to 37.5 nmol/L]) or an alternative cause is suspected based on clinical findings, the alkaline phosphatase level can differentiate between hypophosphatasia and other possible etiologies of osteomalacia.</p><p class="headingAnchor" id="H43496955"><span class="h4">Low alkaline phosphatase (hypophosphatasia)</span><span class="headingEndMark"> — </span>In the setting of a clinical presentation consistent with osteomalacia, a low alkaline phosphatase level suggests hypophosphatasia as the underlying etiology. Alkaline phosphatase is a marker of bone turnover and can be low in any setting where bone turnover is low such as in young, healthy women. Low alkaline phosphatase is not necessarily a pathologic finding unless accompanied by a clinical scenario suggesting osteomalacia. Conversely, the lower limit of the normal range varies across alkaline phosphatase assays, and a low value that falls within the reference range does not invariably exclude hypophosphatasia. In hypophosphatasia, total and bone-specific alkaline phosphatase levels are typically low while the serum calcium and phosphate concentrations are normal. Reduced activity of the alkaline phosphatase enzyme results in accumulation of substrates, including phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5'-phosphate (PLP), in blood and urine. In patients not taking a vitamin B6 (<a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a>) supplement, elevated levels of plasma PLP and urine phosphoethanolamine are markers of hypophosphatasia [<a href="#rid26">26,27</a>]. The diagnosis is confirmed by genetic testing of the <em>ALPL</em> gene. However, disease severity is highly variable and does not clearly correlate with specific pathogenic variants or measured alkaline phosphatase levels [<a href="#rid28">28-31</a>]. (See  <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia", section on 'Hypophosphatasia'</a>.)</p><p class="headingAnchor" id="H1096443125"><span class="h4">Normal or elevated alkaline phosphatase</span><span class="headingEndMark"> — </span>If the alkaline phosphatase is normal or elevated, the serum phosphate level helps to differentiate among potential etiologies.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low serum phosphate</strong> – Osteomalacia with hypophosphatemia may result from primary renal phosphate wasting and/or secondary hyperparathyroidism.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normal PTH level</strong> – The absence of secondary hyperparathyroidism suggests primary renal phosphate wasting, although secondary hyperparathyroidism may be evident in X-linked hypophosphatemia. In adults, primary renal phosphate wasting is usually caused by acquired conditions, such as tumor-induced osteomalacia or Fanconi syndrome. Nonetheless, some hereditary hypophosphatemic disorders may present initially during adulthood.</p><p></p><p class="bulletIndent2">In primary renal phosphate wasting, serum calcium and 25(OH)D levels are normal, PTH is usually normal but may be mildly elevated, and serum alkaline phosphatase is often high. Serum phosphate is low with elevated phosphate clearance, and hypophosphatemia is often more severe than in hypophosphatemia due to hyperparathyroidism. (See  <a class="medical medical_review" href="/z/d/html/835.html" rel="external">"Hypophosphatemia: Evaluation and treatment"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hereditary hypophosphatemia</strong> – Forms of hereditary hypophosphatemia that may present initially in adulthood are autosomal dominant hypophosphatemia, X-linked hypophosphatemia, and hypophosphatemic rickets with hypercalciuria. The clinical features and diagnosis of these disorders are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Tumor-induced osteomalacia</strong> – In adults with tumor-induced osteomalacia, hypophosphatemia results from tumoral production of a phosphaturic hormone, usually FGF23. A low or low-normal 1,25-dihydroxyvitamin D level and an elevated serum FGF23 level suggest the diagnosis [<a href="#rid32">32-34</a>], which warrants efforts to localize the underlying tumor. Depending on the specific assay used, the FGF23 level may fall within the reference range. In the absence of overt FGF23 elevation, a 1,25-dihydroxyvitamin D level that is low or inappropriately normal in the setting of hypophosphatemia suggests an FGF23-mediated process. (See  <a class="medical medical_review" href="/z/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia", section on 'Tumor-induced osteomalacia'</a> and  <a class="medical medical_review" href="/z/d/html/830.html" rel="external">"Hypophosphatemia: Causes of hypophosphatemia", section on 'Increased urinary excretion'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Fanconi syndrome</strong> – Fanconi syndrome describes generalized proximal tubular dysfunction. Hypophosphatemia is accompanied by hypouricemia, aminoaciduria, and glucosuria, as well as proximal (type 2) renal tubular acidosis due to bicarbonate wasting. In contrast to FGF23-mediated hypophosphatemia, the serum 1,25-dihydroxyvitamin D level in Fanconi syndrome is typically elevated or in the high-normal range. In adults, Fanconi syndrome is usually acquired due to multiple myeloma, medications, or exposure to heavy metals  (<a class="graphic graphic_table graphicRef68165" href="/z/d/graphic/68165.html" rel="external">table 4</a>). The diagnosis is established through demonstration of multiple proximal tubular defects and identification of an underlying cause. Heavy metals in the urine may be increased if they are the underlying cause. (See  <a class="medical medical_review" href="/z/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Proximal (type 2) RTA'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Elevated PTH level</strong> – Osteomalacia with hypophosphatemia due to secondary hyperparathyroidism may be caused by isolated proximal renal tubular acidosis or nutritional osteomalacia due to low calcium intake.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Isolated proximal renal tubular acidosis</strong> – Proximal (type 2) renal tubular acidosis is characterized by hyperchloremic metabolic acidosis and hypophosphatemia. In this setting, acidosis-induced hypercalciuria leads to secondary hyperparathyroidism and increased phosphaturia. Unlike Fanconi syndrome, isolated proximal renal tubular acidosis does not present with other tubular defects, primary renal phosphate wasting is absent, and, consequently, hypophosphatemia is generally milder. Isolated proximal renal tubular acidosis is rare. (See  <a class="medical medical_review" href="/z/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Proximal (type 2) RTA'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Nutritional osteomalacia (isolated calcium deficiency)</strong> – Although nutritional osteomalacia is usually due to vitamin D deficiency, it rarely may be caused by isolated calcium deficiency. In contrast to proximal renal tubular acidosis, urine calcium is very low, and metabolic acidosis is absent. The diagnosis is supported by a history of malabsorption and/or negligible intake of calcium-containing foods  (<a class="graphic graphic_table graphicRef67824" href="/z/d/graphic/67824.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal or elevated serum phosphate</strong> – If hypophosphatemia is absent, clinical history and estimated glomerular filtration rate (eGFR) help determine the underlying etiology.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mineralization inhibitors</strong> – Mineralization inhibitors include aluminum, fluoride, and heavy metals, and exposure usually can be determined through clinical history. In skeletal fluorosis, serum calcium and phosphate are typically normal and alkaline phosphate is elevated. Serum, urine, and bone fluoride content are increased [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia", section on 'Mineralization inhibitors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disorders of bone matrix</strong> – In the bone matrix disorders fibrogenesis imperfecta and axial osteomalacia, alkaline phosphatase, calcium, phosphate, and vitamin D are usually normal. As laboratory findings are typically normal in these rare disorders, differentiation from osteoporosis may be difficult. Bone biopsy is often required to establish the diagnosis. (See <a class="local">'Bone biopsy if the diagnosis or etiology remains uncertain (rarely performed)'</a> below and  <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia", section on 'Defective bone matrix'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic kidney disease</strong> – In individuals with chronic kidney disease (eGFR &lt;60 mL/min/1.73 m<sup>2</sup>), diminished renal 1-alpha-hydroxylase activity leads to reduced formation of 1,25-dihyrdoxyvitamin D. A low 1,25-dihydroxyvitamin D level and elevated PTH support chronic kidney disease as an underlying etiology of osteomalacia. Phosphate retention occurs early in chronic kidney disease, so hypophosphatemia is absent despite secondary hyperparathyroidism. Chronic kidney disease-related bone disease often has a mixed skeletal pathology that can include osteomalacia and always warrants additional evaluation. (See  <a class="medical medical_review" href="/z/d/html/7239.html" rel="external">"Evaluation of renal osteodystrophy"</a>.)</p><p></p><p class="headingAnchor" id="H3274341320"><span class="h2">Bone biopsy if the diagnosis or etiology remains uncertain (rarely performed)</span><span class="headingEndMark"> — </span>Bone biopsy using double <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> labeling is infrequently performed in clinical practice and is indicated only when the diagnosis of osteomalacia is uncertain or noninvasive testing fails to identify the cause. Bone biopsy may be performed if chronic kidney disease-mineral and bone disorder (CKD-MBD) is suspected [<a href="#rid35">35</a>], and evaluation for renal osteodystrophy is the most common indication for biopsy [<a href="#rid36">36</a>]. Biopsy also may be needed to assess for one of the rare disorders of defective bone matrix, such as axial osteomalacia or fibrogenesis imperfecta. (See  <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia", section on 'Defective bone matrix'</a>.)</p><p>The histomorphometric characteristics of osteomalacia include  (<a class="graphic graphic_picture graphicRef61773" href="/z/d/graphic/61773.html" rel="external">picture 1</a>) [<a href="#rid37">37,38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged mineralization lag time (an index of the time interval between matrix apposition and its subsequent mineralization)</p><p class="bulletIndent1"><span class="glyph">●</span>Excess osteoid (unmineralized bone matrix) accumulation</p><p class="bulletIndent2"><span class="glyph">•</span>Widened osteoid seams</p><p class="bulletIndent2"><span class="glyph">•</span>Increased osteoid volume</p><p></p><p>All of these features are necessary for the histomorphometric diagnosis because other disorders may show one of these findings. Wide osteoid seams reflecting high bone turnover, for example, can be seen with hyperthyroidism, Paget disease of bone, and hyperparathyroidism. However, the mineral apposition rate is elevated in these disorders in contrast to the low values seen in osteomalacia. (See  <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Other causes of bone fractures, bone pain, and reduced bone mineral density (BMD) include osteoporosis, malignancy, Paget disease of bone, and hyperparathyroidism. Most of these diagnoses can be distinguished from osteomalacia by the clinical history, physical examination, and a combination of laboratory and radiologic studies. Bone biopsy using double <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> labeling may be performed in rare cases that are difficult to diagnose using noninvasive methods [<a href="#rid39">39</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteoporosis</strong> – Osteoporosis most commonly affects postmenopausal women, older adults (age &gt;65 years), and patients treated with chronic glucocorticoid therapy but also can affect adults without these risk factors. In the absence of fractures, osteoporosis is not associated with bone pain. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment"</a> and  <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"</a>.)</p><p></p><p class="bulletIndent1">A distinction between osteoporosis and osteomalacia is critical because individuals with osteomalacia should <strong>not</strong> receive treatment with bisphosphonates, <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>, or other osteoporosis medications; in such patients, treatment with antiresorptive medications may exacerbate hypocalcemia and bone disease [<a href="#rid40">40</a>]. (See <a class="local">'Vitamin D deficiency'</a> below.)</p><p></p><p class="bulletIndent1">In osteoporosis, serum levels of calcium, phosphate, parathyroid hormone (PTH), and alkaline phosphatase are normal, although alkaline phosphatase levels can be low in patients treated with potent antiresorptive osteoporosis therapies or elevated in the setting of fracture healing. In contrast, most etiologies of osteomalacia lead to abnormal findings in one or more of these laboratory values  (<a class="graphic graphic_table graphicRef65400" href="/z/d/graphic/65400.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef142633" href="/z/d/graphic/142633.html" rel="external">algorithm 1</a>) [<a href="#rid41">41</a>]. Although 25-hydroxyvitamin D (25[OH]D) levels may be low in patients with osteoporosis and some patients may have secondary PTH elevation, very low 25(OH)D levels (eg, &lt;12 to 15 ng/mL [30 to 37.5 nmol/L]) should raise clinical suspicion for osteomalacia as an alternative or coexisting diagnosis. (See <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1">Reduced BMD does not distinguish osteoporosis from osteomalacia. Patients with osteomalacia due to vitamin D deficiency may have markedly reduced spine, hip, and forearm BMD. (See <a class="local">'Vitamin D deficiency'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paget disease</strong> – In patients with Paget disease of bone, alkaline phosphatase is elevated, but bone scintigraphy and radiographic findings are unique. Plain radiographs of involved areas show cortical thickening, expansion, coarsening of trabecular markings and mixed areas of lucency and sclerosis. If plain radiographs do not demonstrate such characteristic findings, bone scintigraphy may be needed to establish the diagnosis, particularly during earlier stages of disease. (See  <a class="medical medical_review" href="/z/d/html/5601.html" rel="external">"Clinical manifestations and diagnosis of Paget disease of bone"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple myeloma</strong> – In patients with multiple myeloma, weakness, fatigue, and bone pain are common. Conventional radiography often reveals lytic lesions, as well as diffuse osteopenia and vertebral fractures. Many patients have anemia and abnormal kidney function at diagnosis, whereas most patients with osteomalacia have normal kidney function. In multiple myeloma, alkaline phosphatase is usually normal, and hypercalcemia may be present. Multiple myeloma can cause Fanconi syndrome/proximal renal tubular acidosis in adults [<a href="#rid42">42</a>] and therefore also may be in the differential etiology for osteomalacia. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary hyperparathyroidism</strong> – In patients with primary hyperparathyroidism, both PTH and calcium are elevated, whereas calcium levels are either low or normal in most causes of osteomalacia. (See  <a class="medical medical_review" href="/z/d/html/2029.html" rel="external">"Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H1318839684"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment of osteomalacia depends on the underlying etiology.</p><p class="headingAnchor" id="H4071500"><span class="h2">Vitamin D deficiency</span><span class="headingEndMark"> — </span>Patients with osteomalacia due to vitamin D deficiency should receive vitamin D supplementation and achieve adequate calcium intake  (<a class="graphic graphic_table graphicRef71669" href="/z/d/graphic/71669.html" rel="external">table 5</a>). Vitamin D supplementation leads to a dramatic improvement in muscle strength and bone tenderness within weeks, and adequate calcium intake augments these therapeutic effects. Bone mineral density (BMD) typically improves within three to six months of treatment initiation [<a href="#rid8">8</a>].</p><p>Such patients should <strong>not</strong> receive treatment with bisphosphonates, <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>, or other osteoporosis medications; treatment with antiresorptive medications may exacerbate hypocalcemia and bone disease.</p><p class="headingAnchor" id="H1979566509"><span class="h3">Vitamin D regimen</span><span class="headingEndMark"> — </span>For most patients with osteomalacia due to nutritional vitamin D deficiency, we initially treat with vitamin D, rather than its metabolites. Vitamin D is usually sufficient to normalize 25-hydroxyvitamin D (25[OH]D) levels and is less expensive. In patients with abnormal vitamin D metabolism (eg, due to chronic liver or kidney disease), vitamin D metabolites are often required. The treatment of vitamin D deficiency is reviewed in detail separately and briefly summarized here. (See  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Vitamin D replacement'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low intake or limited sun exposure</strong> – For patients with significant vitamin D deficiency (25[OH]D &lt;12 ng/mL [30 nmol/L]), one common approach is to treat with 25,000 to 50,000 international units (625 to 1250 micrograms) of <a class="drug drug_general" data-topicid="10150" href="/z/d/drug information/10150.html" rel="external">vitamin D2</a> or D3 orally once per week for six to eight weeks, followed by a maintenance dose (eg, 600 to 800 international units of <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">vitamin D3</a> daily) thereafter. However, the efficacy of this practice compared with daily, weekly, or monthly dosing has not been rigorously established. Some patients may require 50,000 international units of vitamin D2 or D3 orally two to three times per week for six to eight weeks. (See  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Dosing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal malabsorption</strong> – In malabsorptive states, oral dosing and duration of treatment depend upon the vitamin D absorptive capacity of the individual patient. Doses of vitamin D of 10,000 to 50,000 international units daily may be necessary to replete patients with significant gastrointestinal malabsorption (eg, due to bariatric surgery, celiac disease, cystic fibrosis). If such doses fail to normalize the vitamin D level, treatment with hydroxylated vitamin D metabolites (calcidiol or <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a>) may be needed, as these metabolites are more readily absorbed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic liver disease</strong> – In severe liver disease, the vitamin D metabolite calcidiol (25[OH]D) may be necessary because it does not require hepatic 25-hydroxylation. The onset of action is more rapid and the half-life of two to three weeks is shorter than that of <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">vitamin D3</a> and similar to that of <a class="drug drug_general" data-topicid="10150" href="/z/d/drug information/10150.html" rel="external">vitamin D2</a>. A typical initial dose is 20 to 40 micrograms daily, but the dose in severe liver disease may be as high as 50 to 200 micrograms daily [<a href="#rid7">7,43</a>]. Calcidiol is not readily available in the United States, so <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> may be used in patients with severe liver disease if vitamin D2 or D3 fails to normalize the 25(OH)D level.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic kidney disease</strong> – In chronic kidney disease, treatment entails replacement of activated 1,25-dihydroxyvitamin D (<a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a>). Both oral and intravenous calcitriol, as well as other vitamin D analogs, can be used. Calcitriol has a rapid onset of action and a short half-life that may require more than once-daily dosing in some patients. Calcitriol increases risk of hypercalcemia, and patients should be followed carefully. It is most useful in adults with decreased calcitriol synthesis, as occurs in chronic kidney disease. Calcitriol treatment in chronic kidney disease is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a>.)</p><p></p><p class="headingAnchor" id="H1158811245"><span class="h3">Calcium intake</span><span class="headingEndMark"> — </span>In addition to vitamin D supplementation, all patients with vitamin D deficiency should maintain a calcium intake of 1000 to 1200 mg per day and achieve the recommended intake for their age group  (<a class="graphic graphic_table graphicRef71669" href="/z/d/graphic/71669.html" rel="external">table 5</a>). Inadequate calcium intake may contribute to the development of osteomalacia [<a href="#rid44">44,45</a>], and the combination of calcium and vitamin D is more likely to produce radiographic evidence of recovery than vitamin D alone [<a href="#rid44">44</a>]. In patients with significant gastrointestinal malabsorption, a higher calcium dose (up to 4 g/day) may be necessary. In patients with hypercalciuria and nephrolithiasis, lower doses of calcium supplementation may be appropriate.</p><p class="headingAnchor" id="H1182393429"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>Treatment monitoring entails serial measurement of BMD, serum alkaline phosphatase, and serum and urinary calcium levels. Increases in urinary calcium excretion and BMD and a decrease in alkaline phosphatase are evidence of recovery from osteomalacia. Healing of osteomalacia may take many months to a year or longer and varies with the severity and duration of vitamin D deficiency [<a href="#rid46">46</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>BMD</strong> – Baseline BMD should be measured by dual-energy x-ray absorptiometry (DXA). BMD values indicate the severity of disease and are monitored during treatment to verify osteoid mineralization. We remeasure BMD one year after treatment initiation. The frequency of subsequent measurements depends on the severity of bone loss and response to vitamin D treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum and urinary calcium</strong> – During treatment, 24-hour urinary calcium excretion and serum levels of alkaline phosphatase, parathyroid hormone (PTH), phosphate, and calcium are monitored regularly (eg, one month and three months after treatment initiation and then every 6 to 12 months). Monitoring the serum calcium concentration allows early detection of hypercalcemia from excessive vitamin D dosing. In most cases, serum calcium and phosphate normalize after a few weeks of treatment, but alkaline phosphatase may remain elevated for several months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum 25(OH)D measurement</strong> – Serum 25(OH)D should be measured approximately two to four months after initiating therapy. The dose should be adjusted as needed to normalize serum 25(OH)D while avoiding hypercalciuria or hypercalcemia due to excessive dosing.</p><p></p><p class="headingAnchor" id="H4071584"><span class="h2">Other causes</span><span class="headingEndMark"> — </span>The management of osteomalacia due to hereditary and acquired renal phosphate wasting syndromes, hypophosphatasia, and Fanconi syndrome/renal tubular acidosis requires treatment of the underlying cause. These are discussed in greater detail elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal phosphate wasting</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hereditary disorders</strong> – The treatment of autosomal dominant hypophosphatemia, X-linked hypophosphatemia, and hypophosphatemic rickets with hypercalciuria is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acquired disorders</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Fanconi syndrome/proximal renal tubular acidosis</strong> – Osteomalacia due to Fanconi syndrome/proximal renal tubular acidosis is treated with vitamin D as well as therapies to correct acidosis. If possible, the precipitating exposure (eg, medication, heavy metal) should be removed. (See  <a class="medical medical_review" href="/z/d/html/2329.html" rel="external">"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Tumor-induced osteomalacia</strong> – Definitive treatment for tumor-induced osteomalacia is complete tumor resection, which leads to reversal of the biochemical abnormalities and healing of the bone disease over a period of weeks to months. If complete tumor resection is not possible, medical management with the human anti-fibroblast growth factor 23 (FGF23) monoclonal antibody <a class="drug drug_general" data-topicid="117667" href="/z/d/drug information/117667.html" rel="external">burosumab</a> is an option. The treatment of tumor-induced osteomalacia is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypophosphatasia</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Enzyme replacement therapy (</strong><strong>asfotase alfa</strong><strong>)</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Perinatal, infantile, or juvenile onset</strong> – Enzyme replacement therapy with <a class="drug drug_general" data-topicid="104963" href="/z/d/drug information/104963.html" rel="external">asfotase alfa</a> is available for perinatal, infantile, and juvenile-onset hypophosphatasia [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia", section on 'Hypophosphatasia'</a> and  <a class="medical medical_review" href="/z/d/html/6281.html" rel="external">"Periodontal disease in children: Associated systemic conditions", section on 'Hypophosphatasia'</a>.)</p><p></p><p class="bulletIndent3">In a preliminary report, infusion of recombinant human tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP, encoded by the<em> ALPL</em> gene) was associated with improvement in skeletal radiographs and in pulmonary and physical function in infants and young children [<a href="#rid48">48</a>]. In other open-label prospective studies including a total of 99 patients with perinatal, infantile, or juvenile-onset hypophosphatasia, enzyme replacement therapy was associated with improved overall survival, ventilator-free survival, growth, and bone mineralization compared with a historic cohort [<a href="#rid47">47</a>]. A subsequent study examined the effects of <a class="drug drug_general" data-topicid="104963" href="/z/d/drug information/104963.html" rel="external">asfotase alfa</a> in 69 infants and young children over several years and found early radiographic and clinical improvement in most patients that was sustained up to six years [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Adolescents and adults with infantile or juvenile-onset hypophosphatasia</strong> – An open-label trial in 19 adolescents and adults (aged 13 to 66 years) with hypophosphatasia (18 of 19 with infantile or juvenile-onset hypophosphatasia) compared <a class="drug drug_general" data-topicid="104963" href="/z/d/drug information/104963.html" rel="external">asfotase alfa</a> (0.3 or 0.5 mg/kg/day) with no treatment (control) for six months followed by a 4.5-year extension phase in which all participants received enzyme replacement therapy [<a href="#rid50">50</a>]. Participants who received asfotase alfa during the primary treatment phase exhibited a decrease in mineralization lag time after one year of treatment. In the overall cohort, median distance walked during the six-minute walk test increased between baseline and five years. In a small subset of adult participants (n = 6) with long-term follow-up, improvement in functional disability was lost after discontinuation of enzyme replacement therapy [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Adult-onset hypophosphatasia</strong> – Management of adult-onset hypophosphatasia usually entails symptom-directed interventions to treat pain, dental manifestations, and/or fractures. <a class="drug drug_general" data-topicid="104963" href="/z/d/drug information/104963.html" rel="external">Asfotase alfa</a> is less well studied in adult-onset hypophosphatasia. Although adults with a history of childhood-onset hypophosphatasia have been included in studies of asfotase alpha, very few adults reporting adult age of symptom onset have been included in these studies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Osteoporosis medications (avoid use)</strong> – In individuals with hypophosphatasia, antiresorptive therapies should be avoided [<a href="#rid52">52</a>]. Anabolic osteoporosis therapies have been studied in very few patients [<a href="#rid53">53-55</a>]. A primary challenge to this strategy is that antiresorptive therapy is typically required after anabolic agents are discontinued to prevent bone loss; however, in individuals with hypophosphatasia, antiresorptive therapy is contraindicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone matrix disorders</strong> – For patients with rare skeletal disorders of defective bone matrix (axial osteomalacia and fibrogenesis imperfecta), no established therapies exist, although a report of two brothers with fibrogenesis imperfecta reported clinical, radiographic, and histologic improvement following treatment with <a class="drug drug_general" data-topicid="9456" href="/z/d/drug information/9456.html" rel="external">recombinant human growth hormone</a> [<a href="#rid56">56</a>]. Axial osteomalacia does not appear to progress over time. In contrast, patients with fibrogenesis imperfecta develop severe skeletal pain, debilitating fractures, and progressive immobility [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia", section on 'Defective bone matrix'</a>.)</p><p></p><p class="headingAnchor" id="H981524"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>Severe vitamin D deficiency can result in osteomalacia during pregnancy [<a href="#rid57">57-59</a>]. Risk factors for osteomalacia during pregnancy include limited sun exposure due to protective clothing, malabsorption (eg, celiac disease, cystic fibrosis, gastric bypass surgery), and malnutrition.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Pregnant women with osteomalacia have similar symptoms as nonpregnant adults. They may present with persistent and nonspecific musculoskeletal pain and inability to bear weight. In some case reports, women presenting with fractures in pregnancy were found to have severe osteomalacia [<a href="#rid59">59,60</a>]. Severe osteomalacia has been associated with cephalopelvic disproportion, necessitating cesarean delivery [<a href="#rid60">60</a>]. (See <a class="local">'Clinical findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory evaluation</strong> – Biochemical findings are similar to those in nonpregnant adults, but results should be interpreted in the context of expected changes in calcium metabolism during normal pregnancy; these include lower total serum calcium, elevated 1,25-dihydroxyvitamin D (particularly in the third trimester), and lower parathyroid hormone (PTH) levels [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Pregnant individuals with osteomalacia should receive adequate calcium (approximately 1000 to 1500 mg daily) and vitamin D. We typically start with 2000 to 4000 international units of <a class="drug drug_general" data-topicid="10150" href="/z/d/drug information/10150.html" rel="external">vitamin D2</a> or D3 daily. We measure 24-hour urinary calcium and serum levels of 25-hydroxyvitamin D (25[OH]D) and calcium one month and three months after treatment initiation, then less frequently until 24-hour urinary calcium excretion is normal. If the initial vitamin D dose does not normalize serum 25(OH)D after three to four months, the dose can be increased by 1000 to 2000 international units/day, with continued monitoring of urinary calcium and serum 25(OH)D and calcium. Monitoring the serum calcium concentration allows early detection of hypercalcemia from excessive vitamin D dosing. The dose of vitamin D should be decreased as needed to prevent hypercalciuria or hypercalcemia.</p><p></p><p class="bulletIndent1">In case reports, pregnant females with severe osteomalacia (diagnosed at the time of delivery) were successfully treated with high-dose vitamin D (600,000 international units intramuscularly as a single dose, after delivery) and calcium supplementation (up to 1.5 g daily) [<a href="#rid59">59,60</a>]. The administration of such high doses of vitamin D during pregnancy has not been adequately studied. In case series from the 1960s, pregnant females with osteomalacia were safely treated with calcium and vitamin D 3000 to 6000 international units daily [<a href="#rid62">62</a>]. Subsequent trials have evaluated vitamin D dosing in pregnant females with vitamin D deficiency, but no participants had vitamin D deficiency of sufficient severity and duration to cause osteomalacia [<a href="#rid63">63,64</a>]. These trials are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Pregnancy'</a>.)</p><p></p><p class="headingAnchor" id="H4483926"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Clinical manifestations of osteomalacia include bone pain and tenderness, muscle weakness, difficulty walking, and a waddling gait. Laboratory findings depend on the underlying etiology. Radiographic evidence of reduced bone mineral density (BMD) with thinning of the cortex is the most common imaging finding but is very nonspecific. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whom to evaluate</strong> – Osteomalacia should be suspected in any adult with bone pain and tenderness, particularly in association with risk factors such as gastrointestinal malabsorption, chronic liver disease, or chronic kidney disease. (See <a class="local">'Whom to evaluate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic and etiologic evaluation </strong>– The diagnosis is based upon a combination of clinical features, laboratory results, and radiographic findings.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical history</strong> – Clinical history should include characteristic symptoms (bone pain and tenderness, muscle weakness), prior fracture(s), and potential risk factors for specific etiologies. (See <a class="local">'Clinical history and physical examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Skeletal imaging</strong> – We obtain plain radiographs of the spine and other skeletal regions based on localized signs and symptoms (eg, areas of pain, tenderness, or deformity). Radiographic findings of hallmark vertebral body changes or Looser zones are consistent with osteomalacia and help confirm the diagnosis. BMD measurement is not required for the diagnosis of osteomalacia, and reduced BMD does not distinguish osteoporosis from osteomalacia. (See <a class="local">'Skeletal imaging for suspected osteomalacia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory tests</strong> – Laboratory findings are used to both confirm the diagnosis of osteomalacia and to determine the underlying etiology  (<a class="graphic graphic_table graphicRef65400" href="/z/d/graphic/65400.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef142633" href="/z/d/graphic/142633.html" rel="external">algorithm 1</a>). Initial laboratory evaluation should include measurement of serum concentrations of calcium, phosphate, alkaline phosphatase, 25-hydroxyvitamin D (25[OH]D), parathyroid hormone (PTH), electrolytes, blood urea nitrogen (BUN), and creatinine. (See <a class="local">'Laboratory tests'</a> above.)</p><p></p><p class="bulletIndent2">In osteomalacia due to vitamin D deficiency, 25(OH)D is typically very low (&lt;12 to 15 ng/mL [30 to 37.5 nmol/L]). Other biochemical findings of osteomalacia due to vitamin D deficiency include low to low-normal calcium and phosphate levels, elevated PTH, and elevated alkaline phosphatase (both total and bone specific). (See <a class="local">'Severe vitamin D deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment of osteomalacia depends on the underlying etiology.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vitamin D deficiency</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Treatment</strong> – Many clinicians treat nutritional deficiency (25[OH]D &lt;12 ng/mL [30 nmol/L]) with 25,000 to 50,000 international units (625 to 1250 micrograms) of <a class="drug drug_general" data-topicid="10150" href="/z/d/drug information/10150.html" rel="external">vitamin D2</a> or D3 orally once per week for six to eight weeks, followed by a maintenance dose (eg, 600 to 800 international units of <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">vitamin D3</a> daily) thereafter. Higher doses may be needed in the setting of gastrointestinal malabsorption. In addition to vitamin D supplementation, all patients with vitamin D deficiency should maintain a calcium intake of 1000 to 1200 mg per day and achieve the recommended intake for their age group  (<a class="graphic graphic_table graphicRef71669" href="/z/d/graphic/71669.html" rel="external">table 5</a>). (See <a class="local">'Vitamin D deficiency'</a> above and  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Dosing'</a>.)</p><p></p><p class="bulletIndent3">In patients with osteomalacia due to severe vitamin D deficiency, vitamin D repletion can lead to a dramatic improvement in muscle strength and bone tenderness within weeks.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Monitoring</strong> – After treatment initiation, serum levels of alkaline phosphatase, PTH, and calcium and urinary calcium excretion should be monitored (eg, initially after one month and three months, and then less frequently [every 6 to 12 months]). Serum 25(OH)D should be measured approximately two to four months after initiating therapy. The vitamin D dose should be adjusted as needed to normalize serum 25(OH)D while avoiding hypercalciuria or hypercalcemia. Laboratory and radiographic abnormalities may take up to one year or longer to resolve. (See <a class="local">'Vitamin D deficiency'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other causes</strong> – Specific treatments for rarer causes of osteomalacia are described briefly above and in more detail elsewhere. (See <a class="local">'Other causes'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Lips P, van Schoor NM, Bravenboer N. Vitamin D-related disorders. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 8th ed, Rosen CJ (Ed), John Wiley &amp; Sons, Inc, Ames 2013.</li><li><a class="nounderline abstract_t">Gifre L, Peris P, Monegal A, et al. Osteomalacia revisited : a report on 28 cases. Clin Rheumatol 2011; 30:639.</a></li><li><a class="nounderline abstract_t">Bhan A, Rao AD, Rao DS. Osteomalacia as a result of vitamin D deficiency. Endocrinol Metab Clin North Am 2010; 39:321.</a></li><li><a class="nounderline abstract_t">Hepp N, Frederiksen AL, Duno M, et al. Biochemical and clinical manifestations in adults with hypophosphatasia: a national cross-sectional study. Osteoporos Int 2022; 33:2595.</a></li><li><a class="nounderline abstract_t">Marini F, Brandi ML. Atypical femur fractures: a distinctive tract of adult hypophosphatasia. Clin Cases Miner Bone Metab 2017; 14:324.</a></li><li class="breakAll">https://rarediseases.info.nih.gov/diseases/6734/hypophosphatasia (Accessed on August 27, 2021).</li><li><a class="nounderline abstract_t">Basha B, Rao DS, Han ZH, Parfitt AM. Osteomalacia due to vitamin D depletion: a neglected consequence of intestinal malabsorption. Am J Med 2000; 108:296.</a></li><li><a class="nounderline abstract_t">Bhambri R, Naik V, Malhotra N, et al. Changes in bone mineral density following treatment of osteomalacia. J Clin Densitom 2006; 9:120.</a></li><li><a class="nounderline abstract_t">Frame B, Parfitt AM. Osteomalacia: current concepts. Ann Intern Med 1978; 89:966.</a></li><li><a class="nounderline abstract_t">Kim S, Park CH, Chung YS. Hypophosphatemic osteomalacia demonstrated by Tc-99m MDP bone scan: a case report. Clin Nucl Med 2000; 25:337.</a></li><li><a class="nounderline abstract_t">Milkman LA. Multiple spontaneous idiopathic symmetrical fractures. Am J Roentgenol 1934; 32:622.</a></li><li><a class="nounderline abstract_t">Steinbach HL, Kolb FO, Crane JT. Unusual roentgen manifestations of osteomalacia. Am J Roentgenol 1959; 82:863.</a></li><li class="breakAll">Goldring SR, Krane SM. Disorders of calcification: Osteomalacia and rickets. In: Endocrinology, DeGroot LJ (Ed), Grune &amp; Stratton, New York 1979.</li><li><a class="nounderline abstract_t">Rosenthall L. DEXA bone densitometry measurements in adults with X-linked hypophosphatemia. Clin Nucl Med 1993; 18:564.</a></li><li class="breakAll">Whyte MP. Sclerosing bone disorders. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 8th ed, Rosen CJ (Ed), John Wiley &amp; Sons, Inc, Ames 2013.</li><li><a class="nounderline abstract_t">Kurland ES, Schulman RC, Zerwekh JE, et al. Recovery from skeletal fluorosis (an enigmatic, American case). J Bone Miner Res 2007; 22:163.</a></li><li><a class="nounderline abstract_t">de Torrenté de la Jara G, Pécoud A, Favrat B. Female asylum seekers with musculoskeletal pain: the importance of diagnosis and treatment of hypovitaminosis D. BMC Fam Pract 2006; 7:4.</a></li><li><a class="nounderline abstract_t">Jin J, Sun F, Wang G, et al. [The clinical characteristics of 26 cases of hypophosphatemia osteomalacia misdiagnosed as spondyloarthritis]. Zhonghua Nei Ke Za Zhi 2014; 53:847.</a></li><li><a class="nounderline abstract_t">Mirghaderi P, Mortezaei A, Parry JA, et al. Osteomalacia Prevalence, Biochemical Profile, and Histology in Patients with Low-Energy Hip Fractures Over the Age of 45. Calcif Tissue Int 2023; 113:257.</a></li><li><a class="nounderline abstract_t">Vilaca T, Velmurugan N, Smith C, et al. Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports. J Bone Miner Res 2022; 37:1188.</a></li><li><a class="nounderline abstract_t">Saadeh G, Bauer T, Licata A, Sheeler L. Antacid-induced osteomalacia. Cleve Clin J Med 1987; 54:214.</a></li><li><a class="nounderline abstract_t">Dahir K, Zanchetta MB, Stanciu I, et al. Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience. J Endocr Soc 2021; 5:bvab099.</a></li><li><a class="nounderline abstract_t">Chang CY, Rosenthal DI, Mitchell DM, et al. Imaging Findings of Metabolic Bone Disease. Radiographics 2016; 36:1871.</a></li><li><a class="nounderline abstract_t">Bolland MJ, Avenell A, Grey A. Prevalence of biochemical osteomalacia in adults undergoing vitamin D testing. Clin Endocrinol (Oxf) 2021; 95:74.</a></li><li><a class="nounderline abstract_t">Lips P. Relative value of 25(OH)D and 1,25(OH)2D measurements. J Bone Miner Res 2007; 22:1668.</a></li><li><a class="nounderline abstract_t">Shajani-Yi Z, Ayala-Lopez N, Black M, Dahir KM. Urine phosphoethanolamine is a specific biomarker for hypophosphatasia in adults. Bone 2022; 163:116504.</a></li><li><a class="nounderline abstract_t">Rush E, Brandi ML, Khan A, et al. Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working Group. Osteoporos Int 2024; 35:1.</a></li><li><a class="nounderline abstract_t">Berkseth KE, Tebben PJ, Drake MT, et al. Clinical spectrum of hypophosphatasia diagnosed in adults. Bone 2013; 54:21.</a></li><li><a class="nounderline abstract_t">Mornet E. Genetics of hypophosphatasia. Arch Pediatr 2017; 24:5S51.</a></li><li><a class="nounderline abstract_t">Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 2016; 12:233.</a></li><li><a class="nounderline abstract_t">Collins MT, Marcucci G, Anders HJ, et al. Skeletal and extraskeletal disorders of biomineralization. Nat Rev Endocrinol 2022; 18:473.</a></li><li><a class="nounderline abstract_t">Endo I, Fukumoto S, Ozono K, et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 2008; 42:1235.</a></li><li><a class="nounderline abstract_t">Bitzan M, Goodyer PR. Hypophosphatemic Rickets. Pediatr Clin North Am 2019; 66:179.</a></li><li><a class="nounderline abstract_t">Endo I, Fukumoto S, Ozono K, et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 2015; 62:811.</a></li><li class="breakAll">KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf (Accessed on July 24, 2023).</li><li><a class="nounderline abstract_t">Isakova T, Nickolas TL, Denburg M, et al. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2017; 70:737.</a></li><li class="breakAll">Parfitt AM. Vitamin D and the pathogenesis of rickets and osteomalacia. In: Vitamin D, second edition, Feldman D, Pike JW, Glorieux FH (Eds), Elsevier Academic Press, San Diego 2005. p.1029.</li><li><a class="nounderline abstract_t">Bhan A, Qiu S, Rao SD. Bone histomorphometry in the evaluation of osteomalacia. Bone Rep 2018; 8:125.</a></li><li class="breakAll">Recker RR. Bone biopsy and histomorphometry in clinical practice. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 8th ed, Rosen CJ (Ed), John Wiley &amp; Sons, Inc, Ames 2013.</li><li><a class="nounderline abstract_t">Cundy T, Que L, Hassan IM, Hughes L. Bisphosphonate-Induced Deterioration of Osteomalacia in Undiagnosed Adult Fanconi Syndrome. JBMR Plus 2020; 4:e10374.</a></li><li><a class="nounderline abstract_t">Bingham CT, Fitzpatrick LA. Noninvasive testing in the diagnosis of osteomalacia. Am J Med 1993; 95:519.</a></li><li><a class="nounderline abstract_t">Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA. Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf) 1995; 43:479.</a></li><li><a class="nounderline abstract_t">Minisola S, Cianferotti L, Biondi P, et al. Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens. Osteoporos Int 2017; 28:3239.</a></li><li><a class="nounderline abstract_t">Thacher TD, Fischer PR, Pettifor JM, et al. A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children. N Engl J Med 1999; 341:563.</a></li><li><a class="nounderline abstract_t">Bishop N. Rickets today--children still need milk and sunshine. N Engl J Med 1999; 341:602.</a></li><li><a class="nounderline abstract_t">Allen SC, Raut S. Biochemical recovery time scales in elderly patients with osteomalacia. J R Soc Med 2004; 97:527.</a></li><li class="breakAll">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468836.htm (Accessed on October 29, 2015).</li><li><a class="nounderline abstract_t">Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 2012; 366:904.</a></li><li><a class="nounderline abstract_t">Hofmann CE, Harmatz P, Vockley J, et al. Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study. J Clin Endocrinol Metab 2019; 104:2735.</a></li><li><a class="nounderline abstract_t">Kishnani PS, Rockman-Greenberg C, Rauch F, et al. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone 2019; 121:149.</a></li><li><a class="nounderline abstract_t">Rockman-Greenberg C, Josse R, Francis M, Mhanni A. Impact of discontinuing 5 years of enzyme replacement treatment in a cohort of 6 adults with hypophosphatasia: A case series. Bone Rep 2022; 17:101617.</a></li><li><a class="nounderline abstract_t">Shapiro JR, Lewiecki EM. Hypophosphatasia in Adults: Clinical Assessment and Treatment Considerations. J Bone Miner Res 2017; 32:1977.</a></li><li><a class="nounderline abstract_t">Camacho PM, Mazhari AM, Wilczynski C, et al. ADULT HYPOPHOSPHATASIA TREATED WITH TERIPARATIDE: REPORT OF 2 PATIENTS AND REVIEW OF THE LITERATURE. Endocr Pract 2016; 22:941.</a></li><li><a class="nounderline abstract_t">Whyte MP, Mumm S, Deal C. Adult hypophosphatasia treated with teriparatide. J Clin Endocrinol Metab 2007; 92:1203.</a></li><li><a class="nounderline abstract_t">Seefried L, Baumann J, Hemsley S, et al. Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. J Clin Invest 2017; 127:2148.</a></li><li><a class="nounderline abstract_t">Bhadada SK, Dhiman V, Mukherjee S, et al. Fibrogenesis Imperfecta Ossium and Response to Human Growth Hormone: A Potential Therapy. J Clin Endocrinol Metab 2017; 102:1750.</a></li><li><a class="nounderline abstract_t">Lee C, Lashari S. Pseudofracture of the neck of femur secondary to osteomalacia. J Bone Joint Surg Br 2007; 89:956.</a></li><li><a class="nounderline abstract_t">Docker C, Starks I, Wade R, Wynn-Jones C. Delayed fixation of displaced bilateral, atraumatic, femoral neck fractures in a patient with pregnancy related osteomalacia. Acta Orthop Belg 2011; 77:402.</a></li><li><a class="nounderline abstract_t">Henry A, Bowyer L. Fracture of the neck of the femur and osteomalacia in pregnancy. BJOG 2003; 110:329.</a></li><li><a class="nounderline abstract_t">Radhika AG, Goel M, Radhakrishnan G, et al. Severe osteomalacia presenting as numerous fractures in late pregnancy. Int J Gynaecol Obstet 2008; 100:92.</a></li><li><a class="nounderline abstract_t">Kovacs CS. Maternal Mineral and Bone Metabolism During Pregnancy, Lactation, and Post-Weaning Recovery. Physiol Rev 2016; 96:449.</a></li><li><a class="nounderline abstract_t">Felton DJ, Stone WD. Osteomalacia in asian immigrants during pregnancy. Br Med J 1966; 1:1521.</a></li><li><a class="nounderline abstract_t">Yu CK, Sykes L, Sethi M, et al. Vitamin D deficiency and supplementation during pregnancy. Clin Endocrinol (Oxf) 2009; 70:685.</a></li><li><a class="nounderline abstract_t">Dawodu A, Saadi HF, Bekdache G, et al. Randomized controlled trial (RCT) of vitamin D supplementation in pregnancy in a population with endemic vitamin D deficiency. J Clin Endocrinol Metab 2013; 98:2337.</a></li></ol></div><div id="topicVersionRevision">Topic 2040 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lips P, van Schoor NM, Bravenboer N. Vitamin D-related disorders. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 8th ed, Rosen CJ (Ed), John Wiley &amp; Sons, Inc, Ames 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20949298" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Osteomalacia revisited : a report on 28 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20511054" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Osteomalacia as a result of vitamin D deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35986118" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Biochemical and clinical manifestations in adults with hypophosphatasia: a national cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29354161" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Atypical femur fractures: a distinctive tract of adult hypophosphatasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29354161" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Atypical femur fractures: a distinctive tract of adult hypophosphatasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11014722" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Osteomalacia due to vitamin D depletion: a neglected consequence of intestinal malabsorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16731441" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Changes in bone mineral density following treatment of osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/363010" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Osteomalacia: current concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10795690" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hypophosphatemic osteomalacia demonstrated by Tc-99m MDP bone scan: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Multiple spontaneous idiopathic symmetrical fractures</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Unusual roentgen manifestations of osteomalacia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Unusual roentgen manifestations of osteomalacia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8344024" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : DEXA bone densitometry measurements in adults with X-linked hypophosphatemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8344024" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : DEXA bone densitometry measurements in adults with X-linked hypophosphatemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17014382" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recovery from skeletal fluorosis (an enigmatic, American case).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16430783" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Female asylum seekers with musculoskeletal pain: the importance of diagnosis and treatment of hypovitaminosis D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25586353" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : [The clinical characteristics of 26 cases of hypophosphatemia osteomalacia misdiagnosed as spondyloarthritis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37326840" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Osteomalacia Prevalence, Biochemical Profile, and Histology in Patients with Low-Energy Hip Fractures Over the Age of 45.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35426179" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3608134" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antacid-induced osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34286168" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27726750" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Imaging Findings of Metabolic Bone Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33866594" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prevalence of biochemical osteomalacia in adults undergoing vitamin D testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17645404" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Relative value of 25(OH)D and 1,25(OH)2D measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35878747" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Urine phosphoethanolamine is a specific biomarker for hypophosphatasia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37982855" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352924" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical spectrum of hypophosphatasia diagnosed in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29405932" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Genetics of hypophosphatasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26893260" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35578027" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Skeletal and extraskeletal disorders of biomineralization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18396126" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30454743" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hypophosphatemic Rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26135520" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26135520" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28941764" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28941764" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29955631" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bone histomorphometry in the evaluation of osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29955631" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Bone histomorphometry in the evaluation of osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32803107" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Bisphosphonate-Induced Deterioration of Osteomalacia in Undiagnosed Adult Fanconi Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7646591" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Noninvasive testing in the diagnosis of osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586624" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28815282" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451461" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451468" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Rickets today--children still need milk and sunshine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15520146" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Biochemical recovery time scales in elderly patients with osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15520146" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Biochemical recovery time scales in elderly patients with osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22397652" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Enzyme-replacement therapy in life-threatening hypophosphatasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30811537" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30576866" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36097602" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Impact of discontinuing 5 years of enzyme replacement treatment in a cohort of 6 adults with hypophosphatasia: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28731215" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hypophosphatasia in Adults: Clinical Assessment and Treatment Considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27042741" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : ADULT HYPOPHOSPHATASIA TREATED WITH TERIPARATIDE: REPORT OF 2 PATIENTS AND REVIEW OF THE LITERATURE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17213282" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Adult hypophosphatasia treated with teriparatide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28436937" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28323922" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Fibrogenesis Imperfecta Ossium and Response to Human Growth Hormone: A Potential Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17673594" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pseudofracture of the neck of femur secondary to osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21846013" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Delayed fixation of displaced bilateral, atraumatic, femoral neck fractures in a patient with pregnancy related osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12628279" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fracture of the neck of the femur and osteomalacia in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17894938" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Severe osteomalacia presenting as numerous fractures in late pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26887676" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Maternal Mineral and Bone Metabolism During Pregnancy, Lactation, and Post-Weaning Recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5941502" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Osteomalacia in asian immigrants during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18771564" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Vitamin D deficiency and supplementation during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23559082" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Randomized controlled trial (RCT) of vitamin D supplementation in pregnancy in a population with endemic vitamin D deficiency.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
